This shareable PDF can be hosted on any platform or network and is fully compliant with publisher copyright.
This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.
If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.
This page is a summary of: The efficacy of immune checkpoint inhibitors and PD-L1 status in patients with advanced non-small cell lung cancer harboring oncogenic driver alterations: Immuno-oncology biomarker study in LC-SCRUM-Japan., Journal of Clinical Oncology, May 2019, American Society of Clinical Oncology (ASCO),
DOI: 10.1200/jco.2019.37.15_suppl.9046.
You can read the full text:
The following have contributed to this page
